title: Specific effects of radioiodine treatment on TSAb and TBAb levels in patients with Graves' disease.
abstract: Radioactive iodine (RAI)-induced changes in the levels of antibodies to the thyroid-stimulating hormone (TSH) receptor (TRAb) in patients undergoing treatment for autoimmune thyroid disease have been well documented. Previous studies have reported effects on the overall level of the antibodies present, TSH-binding inhibitory immunoglobulins (TBII), without detailed studies of specific effects on the levels of thyroid-stimulating (TSAb) or thyroid-blocking antibodies (TBAb). More detailed studies have been reported only in individual cases. In this study, the values of TSAb, TBAb, and TBII were measured longitudinally in 33 patients (27 females and 6 males) who received RAI. The bioassays for TSAb and TBAb were performed in JPO9 cells. Following RAI, there were significant and immediate effects on the values of TBII in 70% of patients. TBII levels fell in 7 patients (20%) (Group 1), rose in 16 patients (48%) (Group 2) or remained unchanged but elevated in 10 patients (32%) (Group 3). In the Group 1 patients, only TSAb were detectable and none of these patients became hypothyroid after treatment. In the 16 patients in Group 2, increases in TBII were attributable to specific increases in TSAb in 7 (44%), in TBAb in 3 (19%), and in both TSAb and TBAb in 3 (19%). There were 3 patients (19%) in this group in whom there was no detectable TSAb or TBAb activity despite the increase in TBII. Six patients from this group became hypothyroid within 6 months of RAI treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Victoria, Australia.
authors.forename: V P
authors.initials: VP
authors.lastname: Michelangeli
authors.forename: C
authors.initials: C
authors.lastname: Poon
authors.forename: D J
authors.initials: DJ
authors.lastname: Topliss
authors.forename: P G
authors.initials: PG
authors.lastname: Colman
mesh_terms: D001681:Biological Assay; D005260:Female; D006111:Graves Disease / Q000276:immunology* / Q000532:radiotherapy*; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology; D007136:Immunoglobulins / Q000032:analysis / Q000276:immunology / Q000528:radiation effects*; D018828:Immunoglobulins, Thyroid-Stimulating / Q000032:analysis / Q000528:radiation effects*; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D011832:Radiation Injuries / Q000150:complications*; D013961:Thyroid Gland / Q000276:immunology; D013972:Thyrotropin / Q000276:immunology
chemical_list: D007136:Immunoglobulins; D018828:Immunoglobulins, Thyroid-Stimulating; D007457:Iodine Radioisotopes; D013972:Thyrotropin